Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors - The Manila Times
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors The Manila Times
AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling - Nature
AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling Nature